香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 ALLEGRO CULTURE LIMITED 律 齊 文 化 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事 會（「董事會」） 謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 八 月 二 十 日（星 期 三）舉 行 董 事 會 會 議，以 考 慮 及 批 准 本 集 團 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 中 期 業 績 及 其 發 佈， 以 及 派 付 中 期 股 息（如 有）之 建 議。 繼續暫停買賣 律齊文化有限公司 （於開曼群島註冊成立並於百慕達繼續經營之有限公司） （股份代號：550） (1)董 事 會 會 議 日 期； 及 (2)繼續暫停買賣 董事會會議日期 於 本 公 佈 日 期，董 事 會 由 執 行 董 事 姚 思 慧 女 士；非 執 行 董 事 鍾 美 ...

公告称，收益减少主要乃由于销售医疗及保健产品减少及电子商务(主要为销售家用及个人护理产品)收 益减少。 律齐文化(00550)发布截至2023年12月31日止年度业绩，该公司取得收益3633.2万港元，同比减少 32.91%;公司权益股东应占亏损3593.4万港元，同比增加306.03%;每股基本亏损7.9港仙。 ...

律齐文化(00550)发布截至2024年6月30日止6个月中期业绩，该集团取得收益1382.9万港元，同比减少 31.6%;公司权益股东应占亏损747.1万港元，同比减少22.6%;每股亏损1.64港仙。 公告称，收益减少乃主要由于广告业务收益减少，以及本集团广告业务以外的业务分部(尤其是电子商 务业务)不再取得收益所致。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 ALLEGRO CULTURE LIMITED 律齊文化有限公司 （於開曼群島註冊成立並於百慕達繼續經營之有限公司） （股份代號：550） (1)截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 的 全 年 業 績 公 佈； 及 (2)繼續暫停買賣 財務摘要 董事會決議不建議派發截至二零二四年十二月三十一日止年度的任何股息。 – 1 – • 收益約為31,500,000港 元，較 二 零 二 三 年 減 少13.3%。 • 毛利約為18,200,000港 元，較 二 零 二 三 年 減 少10.5%。二 零 二 四 年 的 毛 利 率約為57.8%。 • 年度虧損約為12,500,000港 元，較 二 零 二 三 年 減 少65.5%。本 公 司 權 益 股 東應佔年度虧損約為12,500,000港 元，較 二 零 二 三 年 減 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 ALLEGRO CULTURE LIMITED 律齊文化有限公司 （於開曼群島註冊成立並於百慕達繼續經營之有限公司） （股份代號：550） (1)截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 中 期 業 績 公 佈； 及 (2)繼續暫停買賣 財務摘要 董 事 會 議 決 不 宣 派 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 的 任 何 中 期 股 息。 – 1 – • 截至二零二四年六月三十日止六個月的收益約為13.8百 萬 港 元，較 二 零 二三年同期減少31.6%。 • 截至二零二四年六月三十日止六個月的毛利約為10.9百 萬 港 元，較 二 零 二三年同期減少23.3%。截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 的 毛 利 率 約 為78.7%。 • 截至二零二四年六月三十日止六 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 ALLEGRO CULTURE LIMITED 律齊文化有限公司 （於開曼群島註冊成立並於百慕達繼續經營之有限公司） （前稱 Kingkey Intelligence Culture Holdings Limited 京基智慧文化控股有限公司） （股份代號：550） (1)截 至 二 零 二 三 年 十 二 月 三 十 一 日 止 年 度 的 全 年 業 績 公 佈； 及 (2)繼續暫停買賣 財務摘要 董事會決議不建議派發截至二零二三年十二月三十一日止年度的任何股息。 – 1 – • 收益約為36,300,000港 元，較 二 零 二 二 年 減 少32.9%。 • 毛利約為20,300,000港 元，較 二 零 二 二 年 減 少34.5%。二 零 二 三 年 的 毛 利 率約為56.0%。 • 年度虧損約為36,200,000港 元，較 二 零 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 ALLEGRO CULTURE LIMITED 律齊文化有限公司 （於開曼群島註冊成立並於百慕達繼續經營之有限公司） （股份代號：550） (I)股東特別大會之投票表決結果 及 (II)繼續暫停買賣 由於超過50%的 票 數 均 贊 成 決 議 案，決 議 案 已 獲 正 式 通 過 為 本 公 司 之 普 通 決 議 案。 於 股 東 特 別 大 會 日 期，已 發 行 股 份 總 數 為455,534,000股。如 通 函 所 述，立 天 環球有限公司擁有123,037,657股 股 份 之 權 益，相 當 於 本 公 司 已 發 行 股 本 總 額 約27.55%。立 天 環 球 有 限 公 司 由 陳 先 生 全 資 擁 有。因 此，立 天 環 球 有 限 公 司 被 視 為 於 推 廣 合 作 框 架 協 議 及 其 項 下 擬 進 行 ...

Revenue Performance - For the six months ended June 30, 2023, the Group recorded revenue of approximately HK$20.2 million, a decrease of approximately HK$8.8 million or 30% compared to HK$29.0 million in the same period last year[16]. - Revenue from the Recruit Magazine business segment was approximately HK$17.0 million, representing an increase of approximately HK$3.2 million or 23% from the same period last year[5]. - Revenue from the Medical and Health Services business decreased significantly to approximately HK$0.4 million, a decline of 97% compared to approximately HK$12.5 million in the same period last year[6]. - E-Commerce revenue for the six months ended June 30, 2023, was approximately HK$2.9 million, an increase of approximately HK$0.2 million or 7% from the same period last year[7]. - Turnover for the six months ended June 30, 2023, was HK$20,223,000, a decrease of 30.1% compared to HK$29,010,000 in the same period of 2022[64]. - Total revenue for the six months ended June 30, 2023, was HK$20,223,000, a decrease of 30.1% compared to HK$29,010,000 in the same period of 2022[111]. - Revenue from external customers in Hong Kong for the six months ended June 30, 2023, was HK$20,223,000, down from HK$26,300,000 in the same period of 2022, representing a decline of 23.3%[120]. Financial Losses - The Group recorded a loss attributable to equity shareholders of approximately HK$9.7 million for the six months ended June 30, 2023, compared to a loss of approximately HK$2.7 million for the same period last year[23]. - Loss before income tax increased to HK$9,966,000 from HK$1,169,000 year-on-year, reflecting a significant decline in profitability[66]. - The company reported a loss before income tax of HK$9,662,000 for the six months ended June 30, 2023, compared to a loss of HK$2,661,000 in the same period of 2022[139]. - The loss for the period was HK$9,662,000, which is an increase from a loss of HK$2,661,000 in the same period of the previous year[78]. - Basic and diluted loss per share for the period was HK$2.13 cents, compared to HK$0.60 cents in the previous year[66]. Expenses and Costs - Selling and distribution costs increased from approximately HK$4.2 million in the first half of 2022 to approximately HK$6.2 million in the first half of 2023[21]. - Administrative expenses rose to approximately HK$16.4 million, an increase of HK$4.1 million or 33% compared to HK$12.3 million in the same period last year[22]. - Employee benefit expenses increased to HK$12,740,000 in 2023 from HK$11,943,000 in 2022, an increase of 6.7%[133]. - The company recognized a cost of inventories of HK$3,128,000 in direct operating costs for the six months ended June 30, 2023, down from HK$8,616,000 in 2022, a decrease of 63.7%[133]. - Unallocated corporate expenses for the six months ended June 30, 2023, were HK$8,343,000, an increase of 101.3% from HK$4,136,000 in the same period of 2022[113]. Assets and Liabilities - As of June 30, 2023, the Group had net current assets of approximately HK$49.4 million, down from HK$72.1 million as of December 31, 2022[24]. - The Group's current ratio was approximately 6.8 as of June 30, 2023, compared to 6.6 as of December 31, 2022[24]. - The Group's gearing ratio as of June 30, 2023, was 0.00, indicating no bank loans or other borrowings[25]. - Cash and cash equivalents decreased to HK$25,807,000 from HK$69,917,000, indicating a cash outflow situation[68]. - The total trade receivables as of June 30, 2023, amounted to HK$7,670,000, up from HK$5,627,000 as of December 31, 2022, indicating a growth in receivables[154]. - The total trade payables as of June 30, 2023, were HK$267,000, a decrease from HK$1,862,000 as of December 31, 2022, indicating improved payment management[156]. Investments and Capital - The company invested in three securities as of June 30, 2023, compared to two securities as of December 31, 2022[32]. - The company raised approximately HK$103.6 million from the placing of 74,000,000 shares at HK$1.40 per share, intended for general working capital and future business opportunities[38]. - The company plans to revise the use of unutilized net proceeds, reducing the allocation for potential investment opportunities from approximately HK$82 million to HK$49 million, while allocating approximately HK$33 million for general working capital[46]. - The company committed to invest approximately HK$2.4 million in a concert as of June 30, 2023, with no significant contingent liabilities reported[54][60]. - On April 3, 2023, the company entered into a share subscription agreement to invest approximately HK$16 million in Aurora Medical Technology (HK) Corp. Limited, acquiring a 45% equity interest[55]. - The investment in Aurora Medical Technology is seen as having significant potential due to the favorable growth prospects in the global medical and healthcare market, particularly in China[55]. Share Capital and Options - The total issued shares of the company increased to 455,534,000 shares as of June 30, 2023, from 446,614,000 shares as of December 31, 2022[37]. - A total of 8,920,000 share options were exercised during the six months ended June 30, 2023, with 13,380,000 options lapsing, indicating active participation in the share option scheme[160]. - The company granted a total of 22,300,000 share options on January 22, 2021, with an exercise price of HKD 0.38 per share[196]. - As of June 30, 2023, there were no unexercised share options remaining[196]. - The company approved a ten-year Share Award Scheme on December 28, 2022, aimed at recognizing and incentivizing selected employees[199]. Cash Flow and Liquidity - Cash and cash equivalents at the beginning of the period were HK$69,917,000, down from HK$89,194,000 at the beginning of the same period in 2022[74]. - Cash and cash equivalents at the end of the period were HK$25,807,000, significantly lower than HK$82,895,000 at the end of June 2022[74]. - Net cash used in operating activities was HK$22,794,000, a significant increase from HK$420,000 in the same period last year[72]. - For the six months ended June 30, 2023, the net decrease in cash and cash equivalents was HK$44,110,000, compared to a decrease of HK$6,299,000 in the same period of 2022[74]. Related Party Transactions - Amounts due from related parties included HK$100,000 from Kingkey Management Limited, while amounts due to related parties included HK$0 from Kingkey Enterprise Hong Kong Limited, which had a balance of HK$2,014,000 as of December 31, 2022[175]. - The Group's related party transactions included professional fees and marketing expenses, with all service charges determined at market rates[172]. - The remuneration of key management personnel is determined by the remuneration committee based on individual performance and market trends[178]. Other Financial Information - The Group recognized HK$584,000 of right-of-use assets and lease liabilities upon entering a new lease agreement for office equipment on January 1, 2023[75]. - The Group's accumulated loss increased to HK$198,609,000 as of June 30, 2023, from HK$184,543,000 at the same date in 2022[81]. - The Group's investment revaluation reserve increased by HK$96,259,000 during the period[78]. - The Group has three reportable and operating segments: advertising, sale of medical and health products, and e-commerce[104]. - The application of new or amended HKFRSs did not result in significant changes to the Group's accounting policies or financial statements for the current and prior periods[99].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 KINGKEY INTELLIGENCE CULTURE HOLDINGS LIMITED 京基智慧文化控股有限公司 （於開曼群島註冊成立並於百慕達繼續經營之有限公司） （股份代號：550） 截至二零二三年六月三十日止六個月之 中期業績公佈 京 基 智 慧 文 化 控 股 有 限 公 司（「本 公 司」）董 事 會（「董 事 會」）謹 此 提 呈 本 公 司 及 其 附 屬 公 司（統 稱 為「本 集 團」）截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 之 未 經 審 核 綜 合 業 績，連 同 二 零 二 二 年 同 期 之 比 較 數 字 如 下： 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 | --- | --- | |-------|-----------------| | | 二零二二年 | | | ...

Revenue Growth - In FY2022, revenue from the Recruit Magazine business increased by 12.1% to approximately HK$33.1 million[8]. - Revenue from the Medical and Health Services business surged to approximately HK$13.5 million, representing a 153.5% growth compared to approximately HK$5.3 million in the previous year[9]. - The E-commerce service business, launched in May 2022, recorded approximately HK$7.5 million in revenue for the year ended December 31, 2022[10]. - The turnover for the Recruit magazine business increased by 12.1% from approximately HK$29.6 million in 2021 to approximately HK$33.1 million in 2022, attributed to the recovery of the labor market[21]. - The turnover for the medical and health services business surged by 153.5% from approximately HK$5.3 million in 2021 to approximately HK$13.5 million in 2022, driven by increased demand for COVID-19 testing during the fifth wave of the outbreak[22]. - The E-commerce business generated approximately HK$7.5 million in turnover since its launch in May 2022, focusing on household and personal care products[23]. - The total turnover for the year ended December 31, 2022, was approximately HK$54.2 million, representing a 55.2% increase from HK$34.9 million in 2021, mainly due to labor market recovery and demand for COVID-19 testing kits[33]. Financial Performance - The gross profit margin decreased from 72.8% in 2021 to 57.4% in 2022 due to changes in the sales mix[33]. - Other income decreased by 50.5% to approximately HK$2.2 million in 2022, down from HK$4.4 million in 2021, primarily due to the absence of gains from disposals of property, plant, and equipment[34]. - Administrative expenses increased by 1.6% to approximately HK$30.2 million in 2022, mainly due to a rise in staff costs[34]. - As of December 31, 2022, the Group had net current assets of approximately HK$72.1 million, down from HK$96.7 million in 2021, with a current ratio of 6.6[42]. - The Group's gearing ratio as of December 31, 2022, was 0.00, indicating no interest-bearing debts[43]. - Total cash and bank balances as of December 31, 2022, were approximately HK$69.9 million, compared to HK$89.2 million in 2021[47]. - The capital debt ratio was 0.00 as of December 31, 2022, down from 0.02 in 2021, indicating no bank loans or other borrowings[47]. Investment and Future Plans - The company aims to enhance returns to shareholders by focusing on existing businesses and seeking new investment opportunities[15]. - The Group plans to further promote its E-commerce business and explore new business investments to benefit shareholders[26]. - The Group raised approximately HK$103.6 million from the placing of 74,000,000 shares at HK$1.40 per share, with net proceeds of approximately HK$103.0 million[51]. - The Group plans to utilize a substantial portion of the unutilized net proceeds by the end of 2023, focusing on diversifying its business through partnerships[55][56]. - The Group is pursuing strategic investments in the E-commerce sector, targeting brand E-commerce retail and wholesale solutions in China[59]. - As of December 31, 2022, approximately HK$30 million of the net proceeds from the placing was allocated for potential investment opportunities, expected to be utilized by the end of 2023[61]. - On April 3, 2023, the Company entered into a share subscription agreement to invest approximately HK$16 million into Aurora Medical Technology (HK) Corp. Limited, acquiring a 45% equity interest[70][76]. - The investment in Aurora Medical Technology is expected to have significant potential due to the growth prospects in the global medical and healthcare market, particularly in the PRC[70][76]. Shareholder Returns and Dividends - The Board does not recommend any payment of final dividend for the reporting period[67]. - The Group did not recommend any final dividend for the year ended December 31, 2022, consistent with the previous year[146]. - The company did not recommend a final dividend for the year ended December 31, 2022, consistent with the previous year where no dividend was declared[153]. Governance and Compliance - The Company is committed to transparency and compliance in its financial reporting and governance practices[115]. - The Group's Environmental, Social and Governance Report for the year ended December 31, 2022, will be published on April 28, 2023[80][83]. - The Company is focused on maintaining its reserves, with details provided in the consolidated financial statements[154]. - The Company is currently seeking investment opportunities on a continuous basis and will make announcements as appropriate[151]. Share Options and Securities - The Company has a share option scheme that allows eligible participants to receive options as incentives, with the maximum number of shares issuable under share options not exceeding 1% of the issued share capital in any 12-month period[187]. - As of December 31, 2022, a total of 22,300,000 share options were outstanding, with 8,920,000 options exercised and 13,380,000 options lapsed[194]. - The exercise price of the share options is determined by the Directors and cannot be less than the highest of the closing price on the offer date, the average closing price for the five trading days preceding the offer date, or the nominal value of the shares[193]. - On December 28, 2022, the Company established a share award scheme through a trust deed with an independent trustee to purchase shares for selected employees[199]. - Any share options granted to substantial shareholders or independent non-executive Directors in excess of 0.1% of the shares in issue or with an aggregate value exceeding HK$5,000,000 require shareholder approval[192].